This presentation contains financial forecasts with respect to the Company's projected financial results for the Company for the periods indicated. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from ...

Market Opportunity - The obesity treatment market is expected to reach $54 billion by 2030, driven by GLP-1 drug adoption and growing interest in weight management solutions[11] - Approximately 1% of the eligible population undergoes bariatric surgery each year, highlighting a significant unmet need[9] - The company estimates a massive $50B+ revenue opportunity by 2030[8] Allurion Solution & Results - The Allurion Balloon leads to an average of 15% weight loss in 4 months[28] - Sequential Allurion treatment leads to an average of 23% weight loss[21, 28] - Approximately 33% of Allurion patients have tried a GLP-1 before[21, 22] - The Allurion Balloon has a lower serious adverse event rate, approximately 10x lower than other liquid-filled balloons[21] Business Strategy & Financials - The company is implementing a new commercial plan focused on B2B2C marketing and organic demand creation[43] - A major restructuring in Q4-24 is expected to reduce OPEX by approximately 50% in 2025[46] - The company aims to reduce cash burn by 50% in 2025 from $34 million in 2024[46] US Market & FDA Approval - The AUDACITY FDA pivotal trial showed a greater than 50% responder rate in Allurion Balloon subjects[47, 48] - The company expects to complete PMA submission in 2025 and potentially receive FDA approval and launch in the US in 2026[46, 53]

As filed with the Securities and Exchange Commission on June 25, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 92-2182207 (Primary Standard Industrial Classification Code Number) 11 Huron Drive Natick, MA 01760 (508) 647-4000 If any ...